[1] 邱月虹, 吕志武. 自身免疫性肝炎的研究进展. 肝脏, 2015, 20:81-83. [2] Zak KM, Kitel R, Przetocka S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. STRUCTURE, 2015, 23:2341-2348. [3] 中华医学会风湿病学分会. 自身免疫性肝病诊断和治疗指南. 中华风湿病学杂志, 2011, 15:556-558. [4] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010,51:2193-2213. [5] 柯坤宇, 魏大海, 陈丽芳, 等. 自身免疫性肝炎患者肝组织程序性细胞死亡因子1及其配体1的表达及其与临床的相关性. 肝脏, 2016, 21:911-914. [6] Guan J, Lim KS, Mekhail T, et al. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: a key player against various cancers. ARCH PATHOL LAB MED, 2017, 141:851-861. [7] 熊克宫, 柯坤宇, 陈丽芳,等. 自身免疫性肝炎患者肝内程序性死亡受体1高表达与肝脏炎症活动相关. 中华肝脏病杂志, 2017, 25:263-267. [8] Darb-Esfahani S, Kunze CA, Kulbe H, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. ONCOTARGET, 2016, 7:1486-1499. [9] Zou MX, Peng AB, Lv GH, et al. Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. AM J TRANSL RES, 2016, 8:3274-3287. |